Updated on 10 August 2012
In Japan, Abbott Japan is the marketing and manufacturing authorization holder for Humira, while Eisai is responsible for its distribution. The two companies are working together to promote the product under a "one-brand, one-channel, two-promotion" scheme.
Abbott Japan and Eisai remain committed to ensuring, and providing information on, the proper use of Humira as they seek to make further contributions to improve the quality of life of RA patients.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
